NASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $20.80 +2.46 (+13.41%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Rapport Therapeutics Stock (NASDAQ:RAPP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$18.56▼$20.9850-Day Range$18.27▼$23.0552-Week Range$16.55▼$28.08Volume119,329 shsAverage Volume184,452 shsMarket Capitalization$735.82 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingBuy Company OverviewRapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Rapport Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 653rd out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRapport Therapeutics has received no research coverage in the past 90 days.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.46) to ($3.04) per share.Read more about Rapport Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.74% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 6.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.74% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 6.92%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentRapport Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rapport Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for RAPP on MarketBeat in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have not sold or bought any company stock.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Stock News HeadlinesRapport Therapeutics (NASDAQ:RAPP) Shares Down 4.1% - Here's WhyOctober 4 at 4:58 PM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 7% - Here's What HappenedOctober 4 at 3:43 PM | americanbankingnews.comAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowOctober 4, 2024 | Brownstone Research (Ad)Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 6.2%September 29, 2024 | americanbankingnews.comRapport semestriel Pilier 3 - 30 juin 2024September 17, 2024 | globenewswire.comRapport Therapeutics to Present at Upcoming Epilepsy Medical ConferencesSeptember 5, 2024 | globenewswire.comRapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry SummitAugust 29, 2024 | globenewswire.comThe 3 Best Healthcare Stocks to Buy in August 2024August 12, 2024 | investorplace.comSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $25.01 at the start of the year. Since then, RAPP stock has decreased by 16.8% and is now trading at $20.80. View the best growth stocks for 2024 here. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics (NASDAQ:RAPP) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $1.02. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an IPO on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. When does the company's lock-up period expire? Rapport Therapeutics' lock-up period expires on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period. Who are Rapport Therapeutics' major shareholders? Rapport Therapeutics' top institutional investors include SG Americas Securities LLC (0.01%). View institutional ownership trends. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today10/04/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CUSIPN/A CIK2012593 WebN/A Phone(857) 321-8020FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$35.00 Low Stock Price Target$35.00 Potential Upside/Downside+90.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio42.08 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,376,000Free FloatN/AMarket Cap$648.80 million OptionableN/A BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:RAPP) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.